The company said it will use the proceeds for, among other things, the continued development of its microdroplet-based single-molecule DNA sequencing technology.
Paris-based Scipio will use the seed funding to further develop and commercialize its first prototype kit for single-cell transcriptomics.
GeneNews said that it has decided to make an initial draw down of $500,000 to help "fuel the company's momentum while minimizing dilution."
The company said it will use the proceeds to accelerate development of its gastrointestinal platform, including diagnostics and therapeutics for the GI tract.
The company said it would use the proceeds to continue the expansion of its sales force and bring new skin cancer products to market in 2018.
The firm raised €4.7 million through a conditional placement, and €5.0 million through an unconditional direct subscription.
The startup will use the funds to commercialize its single-cell analysis platform, which is based in part on droplet microfluidic technology licensed from UCSF.
The firm is currently marketing its deision support analysis directly to patients and doctors while working on pilot studies with genomics providers to potentially integrate its analysis into their own reports.
The company is developing a bioinformatics platform that searches billions of molecules to generate a library of compounds to manipulate cell biology.
The company develops technologies for single-cell analysis for use in understanding patient responses to immunotherapies.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.
CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.
In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.